NorthWest Biotherapeutics Inc (NWBO)

[FatCat_Banker]

Type of abstract submitted:

I'm having trouble gauging all of this. So, I'm going to have y'all help me. Below I have summarized the types of abstracts, their depth, and dates due (if applicable).

I all caps'ed the selections that I think applies to us, but, as always, feel free to tell me I'm wrong so long as you explain why.



Presentations:

Oral Abstract Session – 12 minute presentations “representing important clinical and transitional research findings.” Limited selected.

Clinical Science Symposia – “presentation of meritorious abstracts” by an expert that summarizes the field and clinical practice. May cross disease sites or disciplines.

Poster Discussion Sessions – small, grouped discussions.

*General Poster Sessions – poster boards, annual meeting includes Trails In Progress in each track to develop awareness.

Publications:

Publication-Only – “acceptable quality” not selected for annual meeting are put online. (Released May 14)

Abstracts:

Late-Breaking (LB) – “randomized phase II and phase III trails of which no preliminary data are available … by Feb. 4th deadline”, but for which the primary end point is scheduled after that date but before April 1. THE POLICY IS NOT A MECHANISM TO ALLOW FOR UPDATED DATA TO BE SUBMITTED LATER WHEN PRELIMINARY DATA ARE AVAILABLE BY THE ABSTRACT SUBMISSION DEADLINE.

*Trails In Progress (TIP) – (discussed in general poster session) all phases accepted, on-going/have not met endpoints for analysis. INCLUSION OF RESULTS WOULD BE IMPROPER AND STRICTLY FORBIDDEN.



Linda mentioned that, now since submission, they can't disclose information on Direct. That points me to these latter two.

Since Direct is not yet randomized, I feel as though we've submitted a TIP & not a LB. This, though, would mean that no endpoints had been met - that can be made public, yet - as of the time of submission.

Her additional comment of 'encouragement' (she's seen something) tells me that necrosis has recently, potentially been observed but systemic response, as she said, ~"will need a longer period to see."

We are co-authoring with MD Anderson, per Linda. Per the guidelines of the linked site it would mean NW Bio and MD Anderson, if selected, will send an expert each to represent the study - the authors.

My question is, who are they? Who could they be? We can take guesses at the unbounded possibilities of trail dispositions, but, it seems to me, determining who these authors are is more ... finite. Let's work on this.

Anyway, that's my stab in the dark. The link is below. Please feel free to pick apart my post until we think we know what's going on.

A friendly reminder: The annual meeting dates are May 30 to June 3. We will know if we weren't selected, if not announced, if we appear in a publication on May 14th - per the above details. After the DMC ruling on L (which I'm more bullish on every day), it's going to be a long 3 months. Hopefully, after a sturdy stock boost, a long, boring run UP past ICPT with updates on patient enrollment in der Vaterland.

I'll shut up.

http://am.asco.org/selection-abstracts-0